James Harper, MD
Psychiatry · Saint Louis, MONPI 1467765594
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $795 and has fallen 91.2% since, to $70 in 2025.
Across 163 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$458
- Otsuka America Pharmaceutical, Inc.$413
- Corium, LLC$397
- Johnson & Johnson$312
- Sunovion Pharmaceuticals Inc.$245
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$236
- plus $909 from 15 others
What the payments were for
- Food & beverage$2,971100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,971 in reported general payments places this provider in the 80th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 16 | $2,735 |
| Clorazepate Dipotassium | 12 | $735 |
| Haloperidol | 36 | $498 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $424 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $284 |
| Benztropine Mesylate | 19 | $266 |
| Lorazepam | 37 | $181 |
| Gabapentin | 12 | $152 |
| Clonazepam | 21 | $143 |
| Mirtazapine | 12 | $142 |
| Alprazolam | 21 | $92 |
| Divalproex Sodium | 11 | $61 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.